48,868
edits
Line 153: | Line 153: | ||
*Prophylatic TAH-BSO done in [[BRCA1|BRCA carrier]]s - prevents [[serous carcinoma]]. | *Prophylatic TAH-BSO done in [[BRCA1|BRCA carrier]]s - prevents [[serous carcinoma]]. | ||
Incidence of pathology in prophylatic BSOs | Incidence of pathology in prophylatic BSOs in a series of 226 cases:<ref name=pmid22710074>{{Cite journal | last1 = Mingels | first1 = MJ. | last2 = Roelofsen | first2 = T. | last3 = van der Laak | first3 = JA. | last4 = de Hullu | first4 = JA. | last5 = van Ham | first5 = MA. | last6 = Massuger | first6 = LF. | last7 = Bulten | first7 = J. | last8 = Bol | first8 = M. | title = Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. | journal = Gynecol Oncol | volume = 127 | issue = 1 | pages = 88-93 | month = Oct | year = 2012 | doi = 10.1016/j.ygyno.2012.06.015 | PMID = 22710074 }}</ref> | ||
*Invasive carcinoma ~ 0.9%. | *Invasive carcinoma ~ 0.9%. | ||
*STIC ~ 6.2% | *STIC ~ 6.2% |
edits